AtriCure, Inc.ATRCNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-21.83%
↓ 592% below average
Average (39q)
4.44%
Historical baseline
Range
High:66.78%
Low:-35.56%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -21.83% |
| Q2 2025 | 29.99% |
| Q1 2025 | -35.56% |
| Q4 2024 | 66.78% |
| Q3 2024 | 6.63% |
| Q2 2024 | -0.95% |
| Q1 2024 | -4.57% |
| Q4 2023 | 2.17% |
| Q3 2023 | 16.72% |
| Q2 2023 | 13.77% |
| Q1 2023 | 11.49% |
| Q4 2022 | -9.37% |
| Q3 2022 | 2.56% |
| Q2 2022 | 8.53% |
| Q1 2022 | -1.30% |
| Q4 2021 | 22.37% |
| Q3 2021 | -7.49% |
| Q2 2021 | 8.74% |
| Q1 2021 | 3.18% |
| Q4 2020 | 2.79% |
| Q3 2020 | 5.38% |
| Q2 2020 | -13.39% |
| Q1 2020 | -11.52% |
| Q4 2019 | 28.97% |
| Q3 2019 | 3.57% |
| Q2 2019 | 19.91% |
| Q1 2019 | -3.30% |
| Q4 2018 | -1.18% |
| Q3 2018 | -1.14% |
| Q2 2018 | -4.44% |
| Q1 2018 | 17.30% |
| Q4 2017 | -3.08% |
| Q3 2017 | -10.56% |
| Q2 2017 | -6.73% |
| Q1 2017 | -3.20% |
| Q4 2016 | 19.28% |
| Q3 2016 | -9.35% |
| Q2 2016 | 6.55% |
| Q1 2016 | 10.25% |
| Q4 2015 | 19.42% |